Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.
Saved in:
| Title: | Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. |
|---|---|
| Authors: | Delimpasi S; Evangelismos Hospital, Athens, Greece., Špička I; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Butler JP; Bone Marrow Transplant Unit, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia., Stevens DA; Norton Cancer Institute, Louisville, Kentucky, USA., Mesa MG; Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Bygrave C; University Hospital of Wales, Cardiff, UK., Merlo GM; Menarini Group, Florence, Italy., la Porte C; Menarini Group, Machelen, Belgium., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea. |
| Source: | British journal of haematology [Br J Haematol] 2026 Jun; Vol. 208 (6), pp. 2260-2264. Date of Electronic Publication: 2026 Apr 14. |
| Publication Type: | Journal Article; Clinical Trial, Phase III |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
